GleamWall
中文EN

EMMA Emmaus Life Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 822370 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.1%
TTM net income YoY-19.2%
TTM EPS YoY-8.3%
Revenue 3-yr CAGR-21.0%
Net income 3-yr CAGR—

Margins

Gross margin92.1%
Operating margin24.8%
Net margin-61.9%
FCF margin—
EBITDA margin25.2%

Returns

ROE—
ROA-45.1%
ROIC (approx.)—
Asset turnover0.73x

Leverage & solvency

Liabilities / assets487.1%
Debt / equity—
Current ratio0.06x
Interest coverage0.44x

Cash quality & payout

Operating cash flow / net income-0.22x
Accruals ratio-54.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$12.45M$16.65M
Cost of revenue$857,000$1.20M
Gross profit$11.60M$15.45M
R&D expense$313,000$657,000
SG&A expense$8.18M$10.69M
Operating income$231,000-$1.89M
Interest expense$7.13M$5.49M
Pretax income-$7.48M-$6.42M
Income tax$9,000$29,000
Net income-$7.49M-$6.45M
EBITDA$270,000-$1.87M
EPS (basic)-0.12-0.10
EPS (diluted)-0.12-0.10
Weighted avg. shares (diluted)64.04M63.23M
Balance sheet
Cash & equivalents$2.13M$1.39M
Receivables$2.80M$2.62M
Inventory$1.55M$1.64M
Current assets$7.75M$6.77M
PP&E, net$113,000$46,000
Total assets$21.44M$23.60M
Current liabilities$69.07M$63.55M
Long-term debt$27.13M$28.96M
Total debt$27.13M$28.96M
Total liabilities$85.04M$80.08M
Shareholders' equity-$63.61M-$56.48M
Net debt$25.00M$27.58M
Shares outstanding70.19M63.87M
Cash flow statement
Operating cash flow-$11,000-$2.29M
Capital expenditure$1,000$12,000
Free cash flow-$12,000-$2.30M
Investing cash flow$2.17M$2.50M
Financing cash flow-$1.43M-$1.35M
Depreciation & amortization$39,000$22,000
Stock-based compensation$25,000$256,000

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.